Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.

Gut - 1 Oct 2006

Hindorf U, Lindqvist M, Peterson C, Söderkvist P, Ström M, Hjortswang H, Pousette A, Almer S

Abstract excerpt

BACKGROUND: Firm recommendations about the way thiopurine drugs are introduced and the use of thiopurine methyltransferase (TPMT) and metabolite measurements during treatment in inflammatory bowel disease (IBD) are lacking. AIM: To evaluate pharmacokinetics and tolerance after initiation of thiopurine treatment with a fixed dosing schedule in patients with IBD. PATIENTS: 60 consecutive patients with Crohn's...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colitis, Ulcerative
Share to Antimetabolites
Share to Azathioprine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crohn Disease

Share to Dose-Response Relationship, Drug

Share to Mercaptopurine

Share to Methyltransferases

Share to Pyrophosphatases

Source

Open in PubMed Open full text

Identifiers

PMID: 16543290
DOI: 10.1136/gut.2005.074930
PMCID: PMC1856436

Genes

TPMT
ITPA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.PMID 16543290Read ↗

No induction of thiopurine methyltransferase during thiopurine treatment in inflammatory bowel disease.Semantic proximity Read ↗

Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases.Semantic proximity Read ↗

Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine.Semantic proximity Read ↗

Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease.Semantic proximity Read ↗

Implications of tioguanine dosing in IBD patients with a TPMT deficiencySemantic proximity Read ↗

Review article: thiopurines in inflammatory bowel disease.Semantic proximity Read ↗

Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.Semantic proximity Read ↗

Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.Semantic proximity Read ↗

High prevalence of polymorphism and low activity of thiopurine methyltransferase in patients with inflammatory bowel disease.Semantic proximity Read ↗

Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.Semantic proximity Read ↗

Pharmacogenetics of Thiopurines in Inflammatory Bowel DiseaseSemantic proximity Read ↗

Azathioprine and 6‐mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.